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Abstract 
Background: 
Clonidine is an alpha-2 adrenergic agonist which has been used to treat hypertension for over 
40 years. In October 2008, clonidine was approved by the FDA for use as a premedication agent 
prior to sedation. The overall goal of this study is to determine if clonidine can be used as a pre-
operative sedative agent in moderate sedation dentistry and if so, what should be considered a 
safe level.  
The following specific aims were established for this study:  
1. To determine whether patients receiving clonidine required less intravenous 
medications. 
2. To determine if clonidine can lower blood pressure and pulse to a safe level (allowing 
adequate perfusion). 
3. To assess whether larger doses of oral clonidine 0.2 mg are significantly different in 
lowering blood pressure and pulse from lower doses of 0.1 mg. 
 
Methods:  
 This study was a clinical, cross sectional study of patients in a major inner city dental 
clinic that provides free dental care to patients in financial need. Data were collected from 
treatment records completed from March 2012-April 2012.  The associations between study 
sample characteristics and use of clonidine at two dose levels (0.1 mg and 0.2 mg vs. controls) 
were examined. An analysis of variance was undertaken with the Duncan’s, Multiple Range Test 
for comparison of the hemodynamic changes (e.g. systolic, diastolic, mean arterial pressure, 
and pulse) of patients taking clonidine 0.1 mg, clonidine 0.2mg, and the control group. 
 
Results:  
At pre-sedation, the clonidine 0.2 mg group had lower systolic and diastolic blood pressures 
than the 0.1 mg group and the control group. During first intraoperative period, the results 
show the mean systolic blood pressure of 0.2 group was significantly lower than the control 
group. After adjustment for age, BMI, and dose of Versed administered, mean systolic blood 
pressures for the 0.2 mg clonidine dose group were significantly lower at pre- sedation and the 
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first intraoperative times in comparison to the 0.1 mg group and the controls. Diastolic blood 
pressures were not different by the three groups after adjustment in the model. The use of 
clonidine at both dose groups did not significantly change the amount of sedation medication 
required, although the data did suggest more sedatives were required at lower clonidine doses.  
 
 
Conclusion:  
 
This study did not find that the use of clonidine led to a significant reduction in the amount of 
sedation medication needed. The mean systolic blood pressures for the 0.2 mg clonidine dose 
group were significantly lower at pre- sedation and the first intraoperative times in comparison 
to the 0.1 mg group and the controls in the adjusted model; however, there were no significant 
differences across the measurement times for the effect of clonidine on diastolic blood 
pressure.   Further research with a more robust sample size in the dose groups and improved 
clinical trial design characteristics would improve our assessment of the effectiveness of the use 
of clonidine in sedation dentistry.  
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Introduction 
   In dentistry, benzodiazepines are the most common sedatives used to relieve anxiety either 
alone or prior to venous cannulation for moderate sedation (1). There are a variety of choices 
of benzodiazepines including: diazepam, triazolam, midazolam, and lorazepam (1). Also, there 
are other types of drugs for preoperative dental sedation including GABA agonists (zolpidem, 
zaleplon) and antihistamines (hydroxyzine, diahydramine) (1).  
  The most commonly used benzodiazepine in dental practice is triazolam (Halocin) (2). 
Triazolam has safety advantages, such as a relatively short-acting, sedative affect, but it may 
temporarily cause amnesia (but not in doses 0.5 mg or under) (3, 4). On the negative side and 
like other benzodiazepines, triazolam causes relaxation of muscles that support the airway 
which can cause respiratory depression that leads to upper airway obstruction (5). Moreover, 
triazolam causes high blood pressure and tachycardia, indicating patients are in a high 
adrenergic state despite having taken an oral sedative (5). 
  Clonidine is an alpha-2 adrenergic agonist which has been used to treat hypertension for over 
40 years (6). In October (2008), the FDA approved clonidine for use as a premedication agent 
prior to sedation (7). Clonidine reduces anesthetic requirements, reduces post-operative 
shivering, and may reduce post-operative nausea and vomiting (8). Additionally, clonidine has a 
sympatholytic effect, post-operative analgesia, and does not cause respiratory depression 
unless there is overdosing (9). Moreover, clonidine doesn’t cause amnesia (9).   
The overall goal of this study is to determine if clonidine can be used as a pre-operative 
sedative agent in moderate sedation dentistry and if so, what should be considered a safe level. 
This study examines clonidine as a pre-op-sedative agent to accomplish these specific aims: 
1. To determine whether patients receiving clonidine required less intravenous 
medications. 
2. To determine if clonidine can lower blood pressure and pulse to a safe level (allowing 
adequate perfusion). 
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3. To assess whether larger doses of oral clonidine 0.2 mg are significantly different in 
lowering blood pressure and pulse from lower doses of 0.1 mg. 
 Literature review 
  The literature review is the summary of studies which were done for examining the 
advantages of clonidine as pre-op-medication in medicine and dentistry. The literature review 
was collected from PubMed using the terms clonidine in dentistry and clonidine as a pre-
sedative agent. 
 Around 1995, clonidine began being reported in dentistry as an oral premedication prior 
to intravenous sedation (13,14,15). Most of these early studies were done outside of The 
United States.  In Japan (1995), Murai and colleagues (13) performed a single-blind cross over 
study on eight healthy adults with intravenous sedation performed twice on each subject 
(surgical extraction of third molars on both sides). In the clonidine-treated group, the subjects 
were given about 5 micrograms (mcg) per kilogram (kg) (0.35mg for a 70 kg person) of oral 
clonidine every 2 hours before the initiation of intravenous sedation with midazolam.  In the 
control group, midazolam was given alone.   The parameters measured were dose of 
midazolam, change in vital signs, recovery time, amnesia and side effects. It was found that oral 
clonidine given pre-operatively could reduce the dose of intravenous (IV) midazolam by an 
average of 45%; the documented recovery time was notably shorter than the control group as 
well. 
 
 In Italy (1998), Fanini and colleagues (14) used 150 micrograms (0.15 mg) of oral 
clonidine (n=20) or placebo 90 minutes prior to conducting conservative, prosthetic or dental 
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surgery procedures.  A blinded observer recorded salivary flow and blood pressure every 30 
minutes over 2-3 hours, as well as the degree of pain and sedation occurring intra- and post-
operatively.    Results of this study found that clonidine produced significant sedation (p<0.001), 
salivary flow reduction (p<0.001), and lower post-operative pain scores (p<0.05).   After taking 
clonidine, the systolic blood pressure of the patients decreased significantly, but none required 
treatment for hypotension.  Of the patients who received clonidine, 55% positively evaluated 
the experience. 
 
 In a more recent review of clonidine’s use as an oral premedication in dentistry (2005), 
Mutzbauer and Obwegeser (15) suggested that premedication with clonidine blunts the stress 
response to surgical stimuli and also that the narcotic and anesthetic dose can be reduced.  
Furthermore, preoperative myocardial ischemic events can be prevented by application of 
clonidine.   Mutzbauer and Obwegeser found that oral clonidine at a dose of 1.5-2.0 mcg/kg 
(0.105 mg - 0.140 mg in a 70kg person) combines the advantages of benzodiazepines and 
morphine: anxiolysis, sedation and analgesia with stable hemodynamic, and respiration.  
However, clonidine does not have the morphine-related side effects such as nausea and 
vomiting.  Although doses of up to 5 mcg/kg (0.35 mg for a 70kg person) have been used in 
young, healthy patients preoperatively in dental and maxillofacial surgery without significant 
side effects, it appears that clonidine at 2 mcg/kg (0.140 mg in a 70 kg person) should be an 
adequate oral premedication dose for these patients when the procedure is performed under 
local anesthesia in the ambulatory setting.   Other recommendations were that clonidine at 
2mcg/kg (0.140 mg in a 70 kg person), should not be exceeded in elderly patients to avoid 
excessive hypotension and sedation.  Finally, it was noted that bradycardia is a contraindication 
of clonidine. 
 
 In a 2006 study by Hall and colleagues (16), oral clonidine was prescribed as a pre-
sedative (0.1 mg/35kg or 0.2 mg in a 70 kg person) in a randomized, crossover, placebo 
controlled clinical trial with 13 participants.  The purpose of this study was to characterize the 
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effects of consuming oral clonidine before IV diazepam/meperidine sedation using the bi-
spectral index (BIS).  BIS is one of several technologies used to monitor depth of anesthesia.   
 
   Typically, depending on the sedation agents used, drugs are titrated to a pre-
determined BIS value (endpoint) and used to maintain that BIS reading throughout the 
procedure.  However, in moderate (IV or conscious) sedation, attempting to titrate drugs this 
way can result in over-dosage, but use of BIS can act as an effective alarm warning of over 
sedation.  For moderate sedation monitoring, BIS alarms can be set at a value of 70-75.  In this 
study, clonidine significantly increased the numbers of BIS-depressed readings and percent 
memory loss during sedation, while reducing the total diazepam and post-operative analgesic 
dosages by 44% and 55%, respectively.  Systolic, diastolic, and mean arterial blood pressures 
(MAP), as well as pulse rates, were reduced.  Respiratory rate, oxygen saturation, end-tidal 
carbon dioxide, and recovery from sedation were unaffected.  Patients, surgeons, and those 
administering the sedation preferred clonidine over the placebo.  It was concluded that 
clonidine pre-treatment prolonged sedation and amnesia, and stabilized vital signs while 
significantly decreasing diazepam and post-operative analgesic usage.  
 
  In two recent 2012 studies (17, 18) authors compared the clinical effects of oral 
midazolam and oral clonidine.   In the first study by Studer and colleagues (17), the researchers 
compared the anxiolytic and side effects of clonidine 150mcg (0.150 mg) and midazolam 7.5 mg 
for premedication in surgical wisdom tooth extraction in 10 adults.   This study was a 
prospective, randomized, double-blind cross-over trial with the patients undergoing bilateral 
wisdom tooth extractions.  Patients received clonidine 0.150mg or midazolam 7.5mg orally one 
hour before their treatment.  Patients who received clonidine (C) for the first surgery received 
midazolam (M) at the second surgery and vice versa.  The anxiolytic efficacy was evaluated with 
a visual analog scale (VAS) upon admission as well as 30, 50, and 60 minutes after 
administration of the medication.  No other sedation (intravenous or nitrous oxide) was given 
following the oral doses of clonidine or midazolam.  Following the administration of midazolam 
(p<0.03) or clonidine (p<0.02) after 30 minutes, an anxiolytic effect was recorded.   No 
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statistically significant differences in anxiolytic effect (anxiety levels were reduced to the same) 
between the clonidine and midazolam groups were seen.   No significant effects were seen on 
blood pressure and pulse.  Similar side effects were reported, including: dizziness (3 in M group 
and 2 in C group), nausea (1 in M group and 1 in C group), slowing of mental performance and 
concentration (2 in M group), falling asleep (1 in C group), and mild collapse 20 minutes after 
discharge, which disappeared after being placed in a supine position for 2-3 minutes (1 in C 
group).  
 
 The second study (18) compared the clinical effects of oral midazolam and oral clonidine 
prior to general anesthesia in sixty ASA 1-2 children ranging in age from 2-8 years.  Patients 
were randomly assigned to receive either oral clonidine (Group 1, n = 30, 4 mcg/kg) or oral 
midazolam (Group 2, n = 30, 0.5mg/kg) 60 minutes prior to the anesthesia induction.   The two 
groups were similar with respect to age, weight, gender, ASA status, and duration of the 
surgery.  The children judged the taste of clonidine as significantly better that the taste of 
midazolam (p<0.05).  The onset of sedation was 38.5 minutes +/- 12 minutes in the clonidine 
group and 30.5 minutes +/-10 minutes in the midazolam group.  However, the level of sedation 
and quality of the pre-operative anxiolysis was significantly better in the clonidine group 
compared to the midazolam group (p<0.05).  The quality of parental separation (3 point scale 
where 1=poor [anxious or combative], 2=good [anxious but easily assured], and 3=excellent 
[calm/sleeping]) was significantly better in the clonidine group (p<0.05), as was mask 
acceptance for the general anesthesia (p<0.05).  However, a satisfactory quality of induction 
was achieved in both groups.    No adverse effects such as bradycardia, hypotension, 
hypoxemia, or apnea were observed during any of the pre-operative or the post-operative 
periods in either of the groups.   Shivering was not seen in any of the patients in the clonidine 
group but was noted in the midazolam group (13.3%, significant).  
 
 The mechanism of clonidine in preventing shivering is correlated with the inhibition of 
vasoconstriction and a decrease in the shivering threshold (19). Post-operative nausea and 
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vomiting (PONV) were seen in 6.67% of patients in the clonidine group and in 10% of the 
patients in the midazolam group, though values were not significant.  
 
  As we can see in the results and conclusions of the studies, clonidine can be alternative 
of sedation and also can be pre-sedative agent but we need additional research to support 
these studies. In this study, we use clonidine at several doses as a pre-sedative and seek to 
determine if the clonidine regime can reduce the amount of sedation needed. 
 
Methods 
 
 This study was a clinical, cross sectional study of patients in a major inner city dental 
clinic that provides free dental care to patients in financial need. Data were collected from 
treatment records completed from March 2012-April 2012.  Many of the patients had a high 
level of dental anxiety and fear which made them ideal candidates for having dental care under 
moderate sedation. The study was voluntary since the patients could choose to participate or 
not after reading all possible side effects of clonidine and the consent form.  The sedations and 
treatment of these patients were provided as part of an annual course offered to credential 
practicing dentists across the state and region to provide intravenous sedation in their dental 
practices.  
  
 All vital signs were taken in the waiting room as a part of the check-in process. There 
were 104 participants in the study. Of the 104 patients who were seen in the time period, 23 
(14 female, 9 male) consented and met the inclusion criteria for clonidine treatment.  Exclusion 
criteria included hypotension (blood pressure less than 100/70) and/or bradycardia (heart rate 
less than 60 beats per minute). Patients were also excluded if they had any of listed clonidine 
use precautions: kidney disease, heart disease (e.g. coronary artery disease, irregular heart 
rhythm, recent heart attack, depression, blood circulation disorders (e.g. Reynaud’s disease, 
stroke), pregnancy or the consumption of alcoholic beverages.  The remaining 81 patients did 
not receive clonidine treatment and were used as controls; one of them was excluded due to 
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inability to obtain intravenous access, therefore, there were only 80 controls and 103 total 
participants. 
 
 Gender, age, and body mass index were abstracted from the medical records. Patients 
were classified by the American Society of Anesthesiologists (ASA) physical status classification.  
This classification system is a system for determining the health condition of patients before 
surgery (20). The primary determining factor for ASA II status was smokers who smoked at least 
half a pack of cigarettes per day (ppd) for 1-30 years.  Other medical conditions contributing to 
ASA status included hypertension, asthma, diabetes mellitus (type II), as well as a history of 
depression, drug and/or alcohol abuse, heart disease, and pulmonary conditions (COPD, 
bronchitis/emphysema).   
 
Statistical analysis 
All statistical analyses were conducted Using SAS. Descriptive statistics, including Chi-
square tests, were conducted to examine the association between study sample characteristics 
and use of clonidine. An analysis of variance was undertaken with the Duncan’s, Multiple Range 
Test for comparison of the hemodynamic changes (e.g. systolic, diastolic, mean arterial 
pressure, and pulse) of patients taking clonidine 0.1 mg, clonidine 0.2mg, and the control 
group.   This comparison was done at four different times when the patients were seen and 
evaluated: 1) at the patients pre-assessment visit, typically one week prior to the sedation and 
dental procedures; and 2) 30 minutes to 1 hour following clonidine administration for the 
clonidine group, when the patient was brought to dental operative room for pre-sedation 
assessment,   3) intra-operatively: at the beginning of  the parental sedation and dental 
procedure, and 4)  intra-operatively: when  the dental operative is almost done. During the 
intraoperative treatment, the patient’s vital signs, oxygen saturation and level of consciousness 
were recorded every 5 minutes.   Intraoperative sedation and treatment ranged from one to 
two and a half hours depending on the type of dental treatment provided.  Treatment included 
extensive oral surgery, endodontic, operative, and periodontal treatment.    
  
11 
 
A comparison was done to determine if there is a significant difference between the two 
doses of clonidine regarding reduction in the amount of sedation. These doses were compared 
to those of the control group to find out the effectiveness of clonidine on sedation amount. 
These comparisons were evaluated by the Duncan’s Multiple Range Test to determine if there 
are significant differences between means. Using the outcomes of these analysis, a simple 
regression model was generated. The model was refined using backward elimination to 
establish which variables should be kept and included in simple regression model. Based on 
these results, gender, ASA, and Fentanyl doses were eliminated. Age, body mass index, and 
Versed doses were retained in the model. 
 
Results 
  Clinical observation 
The first four patients who were given clonidine 0.2mg had significant hemodynamic 
changes prior to venipuncture.   From the time they received clonidine 0.2 mg significant 
differences in BP, MAP and pulse changes occurred.  In addition, in two of the four patients 
who received oral clonidine 0.2mg were reversed with Flumazenil (Romazicon) 0.2mg due to 
over sedation (as diagnosed by the administering dentist) at the end of their dental procedure.  
One patient had received 5mg IV midazolam, and the other 4mg IV midazolam and 25mcg of IV 
fentanyl.  After this first day’s experience, even though no other side effects were noted, such 
as PONV, fainting, light headiness, drowsiness, dry mouth, or complaints from the patients, it 
was decided to reduce the dose by half for the remainder of the patients electing to receive this 
pre-operation Sedatives. 
 
Primary Results.  
 Of the 101 participants in the study, 49.5% female and 50.5% male. The number of 
participants in clonidine group was 23, with four of them having a dose of 0.2 mg and the 
remaining 19 receiving a dose of 0.1 mg. The control group, composed of 80 persons, had 
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slightly more males than females (53% males). The majority of the patients in the study (42% of 
total) were ages 44-56 years of age. Body mass index was categorized at five levels with 
underweight (16-18.5), normal (18.5-25), over weight (25.30), obese (30-35), and morbidly 
obese (35-40).  More than half (54%) were overweight, obese, or morbidly obese.  
 The comparison of blood pressure (systolic and diastolic), pulse and mean arterial 
pressure (MAP) by levels of clonidine dose (0.2 mg and 0.1 mg and control) are given in Table 2. 
According to Duncan’s Multiple Range Test, initially there is significant difference between 
mean systolic pressures for the clonidine 0.2 mg and 0.1m doses in comparison to the control 
group.  At pre-sedation time, the clonidine 0.2 mg group had lower systolic and diastolic blood 
pressures than the 0.1 mg group and the control group. During first intraoperative period the 
results show systolic mean of 0.2 group was significantly lower than the control group. Finally, 
at the final intraoperative measurement, systolic and diastolic blood pressures were lower in 
the 0.2 mg group compared to the 0.1 mg group with the systolic blood pressure also lower 
than in the control group. With regard to pulse, 0.2mg group had a significantly higher initial 
pulse than the control group but not than the 0.1 mg group. The mean arterial pressure was 
significantly lower in the 0.2 mg group at pre-sedation and at the first intra-operative 
measurement in comparison to the 0.1 mg group and the controls.  
 
The distribution of sedation agents by dose is given in Table 3 for the two levels of clonidine 
and the control group.  Two drugs were the main intra-operative sedation and analgesic agents 
used: midazolam (Versed) (benzodiazepine) and Fentanyl (narcotic).  Diphenhydramine 
(Benadryl) was added in some cases for the patients when more sedation was felt necessary 
and the maximum number of other agents had been reached. The maximum dose of drugs 
given to the dentists to use per patient (due to the course format and pharmacy constraints) 
was midazolam 10mg and fentanyl 100mcg.  However, the cases had treatment planned and if 
the case extended over 90 minutes, more sedative/analgesic agents could be requested and 
used. The result shows no significant difference in the use of sedation drugs by the three drug exposure 
groups, although the data did suggest more sedatives were required at lower clonidine doses. 
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 Finally, Table 4 shows the adjusted model, we can see that after adjusted for age, BMI, and dose 
of Versed administered, mean systolic blood pressures for the 0.2 mg clonidine dose group are 
significantly lower at pre- sedation and the first intraoperative times in comparison to the 0.1 mg group 
and the controls. Diastolic blood pressures were not different by the three groups after adjustment in 
the model. 
 
Discussion 
 
 The purpose of this study was to investigate clonidine as a pre-operative sedative agent 
prior to moderate sedation in dentistry, by considering its advantages as an alpha -2 adrenergic 
agonists.  The data were analyzed to compare means of vital signs and amount of sedation 
needed for clonidine (0.2mg, 0.1mg) and control groups. This comparison was done to find out 
if clonidine can lower vital signs at a safe level and reduce the amount of sedation needed as 
well.   As noted in the previous discussion (literature review), the literature varied on the 
recommended dosing for adults (See appendix table).  
  Although reductions in BP, MAP and pulse did occur with the pre-sedation clonidine 
0.2mg dose, the differences were not as significant in the 19 patients who took the clonidine 
0.1mg when compared to control.  However, given the very small numbers of subjects in the 
0.2 mg clonidine group (N=4), the power is very limited. The only statistically significant effect 
from the adjusted means in the model was the marked reduction in systolic blood pressure in 
the clonidine 0.2 mg group. In comparison to the control group, which as the most stable mean 
blood pressure values (N=80), the reduction is a 23 mm Hg for systolic pressure at pre-sedation 
and a 23mg Hg decrease at the first intraoperative measurement. Although there was some 
indication that smaller doses of sedatives (Versed and Fentanyl) were used for the clonidine 
groups, the study was not large enough to demonstrate statistically significant differences.  
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Comparison to previous studies. 
 The majority of previous studies were examining the use of clonidine as a pre-sedative 
in dentistry were conducted using a randomized, double-blind design.  In most of these studies, 
clonidine was found to be an effective pre-sedative with few side effects. Systolic, diastolic, and 
mean arterial blood pressures (MAP), as well as pulse rates, were reduced with the use of 
clonidine in these studies. It is challenging to compare the results of this study since the design 
did not randomize patients to different medication groups and only 23 of the patients received 
clonidine (and only 4 at the highest dose groups). The change in the administered dose 
followed the reporting of changes in blood pressure, Map, and pulse rate in the initial four 
patients, so the dose was lowered to 0.1 mg in the remaining patients. In general, previous 
studies did not show side effects at this dose level.  These limitations challenge the comparison 
with previous studies.  
Strengths and Limitations.  
This study has many limitations. One main limitation was lack of statistical power due to small 
sample size of all clonidine groups but specifically for the 0.2 dose group.  Originally the 
purpose of the study was to examine the effect of 0.2 mg dose on blood pressure and required 
sedation, but as mentioned some minor side effects were occurring in patients which led to a 
reduction in the dose for the remaining patients. Additional covariates like race and health 
status were not collected in the study nor controlled in the analysis. Therefore, the study 
population is not representative of overall population. Participation was based on convenience 
sampling and therefore random selection and blinding were not employed in the design of the 
study.  
Conclusions and directions for future research. 
This study did not find that the use of clonidine led to a significant reduction in the amount of sedation 
medication needed. The mean systolic blood pressures for the 0.2 mg clonidine dose group were 
significantly lower at pre- sedation and the first intraoperative times in comparison to the 0.1 mg group 
and the controls in the adjusted model; however, there were no significant differences across the 
measurement times for the effect of clonidine on diastolic blood pressure.    
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This study suggests that there are complications in using clonidine at the 0.2 mg dose level. 
Reduction to the 0.1 dose level lessened the complications but may have reduced the 
effectiveness of the drug as a pre-sedative. 
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  Appendix Table   
 
Recommended Adult Dosing for Clonidine (literature review) 
 
Recommen
ded  
Pre-med 
Clonidine 
dose 
Milligram 
(mg) for 
70 kg 
person 
Reference  
Number 
from 
bibliography 
Author and Journal 
0.2 mg  
0.1 mg 
(elderly) 
0.2 mg 1. David Todd.  ADSA.  The pulse. 
0.2 mg 0.2 mg 3.  Hall et al. Anesthesia Progress. (2006) 53:34-42. 
5mcg/kg 0.35 mg 5.  Murai et al.  Anesthesia Progress. (1995) 42:135-138. 
150 mcg 0.15 mg 6.  Fanini et al. Mineral Stomatol. (1998) 47(9):459-64. 
5mcg/kg 0.35 mg 7.  Frank et al. Anasthesiol Intensivmed Notfallmed 
Schmerzther. (2000) 35(7):428-34.  
1.5 mcg/kg 
2.0 mcg/kg 
0.105 mg 
0.14 mg 
8. Mutzbauer et al. Schweiz Monatsschr Zahnmed (2005) 
115(3):214-218. (in German) 
0.1 mg/35 
kg 
0.2 mg 9.  Hall et al.  Journal of Dental Research (2006) 85 (9): 854-
858. 
150 mcg 0.15 mg 10.  Studer et al.  Oral Maxillofac Surg (2012) 16: 341-347.  
4.0 mcg/kg* 
Avg. wt. 2yrs 
=28.4 lbs; or 12.9 
kg 
Avg. wt. 8 yrs = 
57.2 lbs;  
or 25.9 kg 
Ranges= 
0.1 mg 
0.2 mg 
 
11. Mahajan et al. J. of Clinical and Diagnostic Research 
(2012)  
6(5): 870-873. 
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*Body mass index 
~ American Society of Anesthesiologist physical status classification  
# P value refer to Likelihood Ratio Chi-Square test.   
Effective sample size =101; Frequency missing =2 
 
Table 1: Study Population Demographics   
Characteristics Overall  
  
N=102 
 
N (%) 
Clonidine 
0.1 mg 
N=19 
 
N (%) 
Clonidine 
0.2 mg  
N=4 
 
N (%) 
Control 
 
N=80 
 
N (%) 
 
 
P-value# 
 
Sex       
Female 50 (49.5) 10 (20) 4 (8) 36 (72) 
0.05 
Male 51 (50.5) 9 (17.7) 0 (0) 42 (82.3) 
Age       
18-30 19 (18.81) 1 (5.2) 1 (5.3) 17 (89.4) 
0.49 
31-43 29 (22.7) 6 (21.4) 2 (7.1) 20 (71.4) 
44-56 42(41.5) 9(21.4) 1 (2.4) 32 (76) 
>=57 12 (11.9) 3 (25) 0 (0) 9 (75) 
BMI *      
16-18.5 8 ( 7.8) 0(0) 0 (0) 8 (100) 
0.033 
18.5-25 39 (37.8) 10 (25.6) 3 (7.7) 26 (66.7) 
25-30 24 (23.3) 2 (8.33) 0 (0) 22 (91.7) 
30-35 27 (26.2) 5 (18.52) 0 (0) 22 (81.5) 
35-40 5 (4.8) 2 (40) 1 (20) 2 (40) 
ASA Status ~      
I 16 (15.5) 1 (6.25) 0 (0) 15 (93.7) 
0.27 
II 74 (71.8) 17 (23) 4 (5.4) 53 (71.6) 
III 12 (11.6) 1 (8.3) 0 (0) 11 (91.7) 
IV 1 (0.8) 0 (0) 0 (0) 1 (100) 
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Table 2: Comparison of Hemodynamic Changes among the Participants (N=103) 
BLOOD PRESSURE 
PULSE 
MAP* 
Clonidine 0.1 mg   
N=19 
Clonidine 0.2 mg   
N=4 
Control  
N=80 
INITIAL 152A / 89A 
81AB 
121B / 83A 
92A 
135AB / 80A 
77B 
PRE-SEDATION 
 
 
 
133A / 80A 
75A 
97A 
97B / 66B 
85A 
77B 
126A / 77A 
78A 
93A 
FIRST INTRA -
OPERATIVE 
 
 
117AB / 73A 
78A 
98A 
102B / 69A 
77A 
77B 
121A / 73A 
78A 
94A 
FINAL INTRA-
OPERATIVE 
 
 
131A / 81A 
74A 
89A 
96B / 67B 
80A 
80A 
126A / 77AB 
78A 
89A 
 
* MAP=Mean arterial blood pressure 
The symbols letters A, B, and AB indicate significant differences in means according to Duncan’s Multiple 
Range Test; means with the same letters are not significantly different from each other. 
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Table3: Sedation Administration Among the Participants N=103 
Sedative 
Agent 
 
 
 
Clonidine 0.1 mg 
Mean effective A   
N=19 
N (%) 
 
Clonidine 0.2 mg 
Mean effective A   
N=4 
N (%) 
 
Control  
Mean 
effectiveA 
N=80 
N (%) 
P value 
VERSED 
 
   0.502 
 6A 4A 6A  
<=5 9(47) 3(75) 39(48)  
5-10 9(47) 1(25) 37(46)  
>10 1(5.3) 0(0) 2(2.5)  
FENTANYL    0.41 
 63A 25A 71A  
2-50 6(31) 2(50) 10(12.5)  
75-175 8(42) 1(25) 31(38.8)  
24 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Means adjusted for age, body mass index, and the dose of versed administered. 
The symbols letters A.B. AB According to Duncan, s Multiple Rang Test, means with the same letters are not 
significantly different from each other. 
 
 
Table4: Adjusted Means - Systolic and Diastolic Blood Pressure Measurements by 
Clonidine Levels    
 
 
 
 
Clonidine 0.1 mg 
   
N=19 
Clonidine 0.2 mg 
   
N=4 
Control  
 
N=80 
P value 
Pre-Sedation 
Systolic Pressure 131A 104B 127A 0.017 
Diastolic Pressure 79 70 78 0.290 
Intra-Operative (First) 
Systolic Pressure 128A 103B 126A 0.041 
Diastolic Pressure 80 71 77 0.411 
Intra-operative (Final) 
Systolic Pressure 115 107 121 0.142 
Diastolic Pressure 72 72 73 0.862 
